This GLP-1 Stock Could Double by 2030. Here's Why

Viking Therapeutics is positioned to benefit from accelerating GLP-1 demand as the GLP-1 drug market could grow to ~$190B by 2035 (vs. ~$79B last year), with its phase 3 candidate VK2735 and additional programs (oral VK2735 and VK3019). The article frames the setup as “high-risk, high-reward”: successful VK2735 phase 3 results could support approval around mid-to-late 2028 and potentially “generate billions” in annual sales, but failure would likely cause a sharp downside move. With the company valued at ~$4.4B, outcomes around phase 3 completion (in ~12–18 months) and oral side-effect mitigation are key near-term catalysts.

Analysis

The market is still pricing obesity as a growth bucket, but the key mechanism is no longer category expansion alone — it is differentiation under payer scrutiny. If VKTX can narrow the efficacy/tolerability gap with the leaders, it becomes a credible mid-cap re-rating story; if not, the company’s valuation leaves little cushion for another financing cycle or trial delay. That makes the next 12-18 months the real event window, while the 6-18 month structural question is whether obesity turns into a scale game where only LLY/NVO and a few manufacturing-heavy platforms keep pricing power.

Second-order, the biggest loser from a true VKTX success may not be the incumbents’ unit volume but their future margin mix: a better-than-expected entrant raises the bar for promotional spend, payer rebates, and line-extension economics across the space. Conversely, if VKTX’s oral program remains limited by discontinuation, that reinforces the idea that convenience alone is not enough and preserves premium demand for injectable brands and GLP-1 adjacent franchises. The contrarian miss on consensus is that “more GLP-1 competition” can be bearish for the whole basket even when the total market grows, because it shifts bargaining power from innovators to payers.

Near term, this is mostly a catalyst trade, not a fundamental long-only compounding story. The stock can gap materially on phase 3 data, but the downside is nonlinear if efficacy or tolerability falls short of the market’s obesity bar; a miss would likely re-rate the name toward cash-flow optionality rather than platform value. For LLY and NVO, the read-through is nuanced: they are still the quality anchors, but any sign of differentiated combination or oral efficacy from VKTX could slow multiple expansion by reminding investors that the category is not settling into a duopoly.

Key Decisions for Investors

• If expressing upside, use a small-risk VKTX call spread into the next phase 3 data window rather than common stock; the payoff is asymmetric, but only if the readout beats the market’s high bar.
• Pair trade: long VKTX / short XBI over the next 6-18 months to isolate catalyst alpha versus beta, with the thesis that positive obesity data should outperform the biotech basket while a miss is contained by the short.
• Avoid shorting LLY or NVO outright on this story; use any post-data weakness in the leaders as a long entry instead, since the most probable outcome is category growth with modest share churn rather than structural displacement.
• Set a hard risk trigger on VKTX around the next clinical update: if phase 3 shows no meaningful tolerability improvement versus prior program evidence, treat that as a thesis break and exit the trade.
• Watch for payer/market-share commentary from LLY/NVO over the next 1-3 quarters; if rebate intensity or discontinuation issues worsen, it would confirm that competition is compressing economics faster than the market expects.